|
|
Volumn 70, Issue 2, 2013, Pages 88-
|
|
Cabozantinib approved for advanced medullary thyroid cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CABOZANTINIB;
PLACEBO;
ABDOMINAL PAIN;
ADVANCED CANCER;
BLEEDING;
CONSTIPATION;
DIARRHEA;
DIGESTIVE SYSTEM FISTULA;
DIGESTIVE SYSTEM PERFORATION;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG LABELING;
DRUG MECHANISM;
DRUG PACKAGING;
DRUG STORAGE;
ENZYME INHIBITION;
FATIGUE;
HAIR COLOR;
HUMAN;
HYPERTENSION;
MOUTH ULCER;
NAUSEA;
NOTE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RECOMMENDED DRUG DOSE;
SIDE EFFECT;
THYROID MEDULLARY CARCINOMA;
TUMOR GROWTH;
WEIGHT REDUCTION;
|
|
EID: 84872310356
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news130005 Document Type: Note |
|
Times cited : (20)
|
|
References (0)
|
